Literature DB >> 2881217

Some pharmacological properties of Wy 27127 a more selective alpha 2:alpha 1-adrenoceptor antagonist than idazoxan in vitro.

S J Bill, A Boniface, F Haroun, R P McAdams, N Lattimer, K F Rhodes.   

Abstract

Wy 27127 and idazoxan were approximately equipotent as antagonists at alpha 2-adrenoceptors as estimated by their ability to block clonidine-induced inhibition of electrically-evoked contractions of the rat isolated vas deferens. Idazoxan was seven times as potent as Wy 27127, as an antagonist at alpha 1-adrenoceptors as indicated by blockade of methoxamine-induced contractions of the rat isolated anococcygeus muscle. Thus, the alpha 2:alpha 1 selectivity ratio, as calculated from these tests was 407 for Wy 27127 and 76 for idazoxan. Wy 27127 and idazoxan were equipotent in enhancing stimulation-evoked overflow of tritium from rabbit isolated pulmonary arteries preloaded with [3H]-noradrenaline as expected for alpha 2-adrenoceptor antagonists. At higher concentrations both compounds reduced the stimulation-evoked contraction of the pulmonary artery but idazoxan was 15 times as potent as Wy 27127 in this respect. Neither compound had marked antagonist actions at 5-hydroxytryptamine (D), muscarinic, presynaptic dopamine or histamine (H1) receptors or at beta 1-adrenoceptors. Thus, idazoxan and Wy 27127 were equipotent alpha 2-adrenoceptor antagonists in vitro, however, the alpha 2:alpha 1 selectivity of Wy 27127 was considerably greater than that of idazoxan by virtue of weaker alpha 1-adrenoceptor antagonism.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2881217     DOI: 10.1007/bf00569380

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  18 in total

1.  Presynaptic receptors.

Authors:  S Z Langer
Journal:  Nature       Date:  1978-10-12       Impact factor: 49.962

2.  Alpha sympathomimetic inhibition of adrenergic and cholinergic transmission in the rabbit heart.

Authors:  K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1972       Impact factor: 3.000

Review 3.  Alpha-adrenoceptor subclassification.

Authors:  K Starke
Journal:  Rev Physiol Biochem Pharmacol       Date:  1981       Impact factor: 5.545

4.  Effect of duration and frequency of stimulation on the presynaptic inhibition by alpha-adrenoceptor stimulation of the adrenergic transmission.

Authors:  E S Vizi; G T Somogyi; P Hadházy; J Knoll
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1973       Impact factor: 3.000

5.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

6.  Partial agonist effect of 2-[2-(1,4-benzodioxanyl)]-2-imidazoline (RX 781 094) at presynaptic alpha 2-adrenoceptors in rabbit ear artery.

Authors:  N limberger; K Starke
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

7.  Studies on RX 781094: a selective, potent and specific antagonist of alpha 2-adrenoceptors.

Authors:  J C Doxey; A G Roach; C F Smith
Journal:  Br J Pharmacol       Date:  1983-03       Impact factor: 8.739

8.  Prejunctional dopamine receptors modulate twitch responses to parasympathetic nerve stimulation in the rabbit isolated rectococcygeus muscle.

Authors:  G M Drew; A Hilditch
Journal:  Br J Pharmacol       Date:  1984-12       Impact factor: 8.739

9.  Role of the -adrenoceptor in regulating noradrenaline overflow by nerve stimulation.

Authors:  M A Enero; S Z Langer; R P Rothlin; F J Stefano
Journal:  Br J Pharmacol       Date:  1972-04       Impact factor: 8.739

10.  Effects of alpha-adrenoceptor agonists and antagonists and of antidepressant drugs on pre- and postsynaptic alpha-adrenoceptors.

Authors:  J Brown; J C Doxey; S Handley
Journal:  Eur J Pharmacol       Date:  1980-10-03       Impact factor: 4.432

View more
  1 in total

1.  An insulin-releasing property of imidazoline derivatives is not limited to compounds that block alpha-adrenoceptors.

Authors:  A Schulz; A Hasselblatt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.